Padagis Israel
Israel 71 employees Updated 9 July 2026
Padagis Israel is a finished-dose manufacturer based in Israel. It appears in 43 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 27 October 2022 as NAI.
3
registered plants
1 with an FDA FEI number
43
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 27 October 2022 NAI US FDA
- 13 June 2019 NAI US FDA
- 19 July 2018 NAI US FDA
- 22 January 2015 VAI US FDA
- 27 August 2012 VAI US FDA
- 28 January 2010 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Shoham, Israel | Not on file |
| Israel, Israel | 3001904238 |
| Yeruham, Israel | Not on file |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 43 | None |
| EMA | None | 12 |
Comparing suppliers?
Choose your molecules and target markets. Padagis Israel comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- 11 active litigation matters are on record.
- The most recent inspection outcome was NAI, on 27 October 2022.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates